LeMaitre Vascular (NASDAQ:LMAT) Updates Q3 2025 Earnings Guidance

Key Points

• LeMaitre Vascular updated its Q3 2025 earnings guidance, forecasting earnings per share between $0.540 and $0.590 and revenue between $61.2 million and $63.2 million, both slightly above analysts' consensus estimates.
• The company's stock rose 1.5% to $85.60 on a trading volume of 340,794 shares, significantly higher than its average volume.
• CEO George W. LeMaitre sold 76,868 shares at an average price of $85.79, reducing his holdings by 4.10% while still retaining a significant stake in the company.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) updated its third quarter 2025 earnings guidance on Tuesday. The company provided EPS guidance of 0.540-0.590 for the period, compared to the consensus EPS estimate of 0.539. The company issued revenue guidance of $61.2 million-$63.2 million, compared to the consensus revenue estimate of $60.9 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.230-2.370 EPS.

LeMaitre Vascular Stock Up 0.5%

NASDAQ:LMAT traded up $0.49 during mid-day trading on Thursday, reaching $93.72. The stock had a trading volume of 122,340 shares, compared to its average volume of 188,692. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $109.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of 45.53, a price-to-earnings-growth ratio of 2.26 and a beta of 0.79. The stock's 50 day simple moving average is $82.88 and its two-hundred day simple moving average is $86.73.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.03. The firm had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.91%. The company's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 EPS. Equities analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular's payout ratio is presently 40.40%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research reports. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective on the stock in a research note on Wednesday. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, LeMaitre Vascular presently has an average rating of "Hold" and an average target price of $98.00.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 76,868 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the sale, the chief executive officer directly owned 1,796,783 shares of the company's stock, valued at approximately $154,146,013.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 100,000 shares of company stock valued at $8,556,857. Insiders own 9.50% of the company's stock.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently modified their holdings of LMAT. Geneos Wealth Management Inc. increased its stake in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 398 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of LeMaitre Vascular by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier's stock valued at $1,013,000 after buying an additional 539 shares in the last quarter. Royal Bank of Canada increased its position in LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier's stock valued at $9,579,000 after acquiring an additional 1,735 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of LeMaitre Vascular by 5.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 37,709 shares of the medical instruments supplier's stock valued at $3,164,000 after purchasing an additional 1,972 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of LeMaitre Vascular in the first quarter worth about $168,000. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.